X0202 SCHEDULE 13G 0001425738 XXXXXXXX LIVE Common Shares, no nominal value per share 03/31/2026 0002020932 AgomAb Therapeutics NV 00860C102 Posthoflei 1/6 Antwerpen C9 2600 Rule 13d-1(d) Redmile Group, LLC DE 0.00 2735926.00 0.00 2735926.00 2735926.00 N 5.6 IA OO The information in Item 4 relating to the Issuer's common shares, no nominal value per share ("Common Shares"), that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference. Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on April 23, 2026 (the "Form 20-F"). Jeremy C. Green X0 0.00 2735926.00 0.00 2735926.00 2735926.00 N 5.6 HC IN The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference. Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Form 20-F. Redmile Biopharma Investments III, L.P. DE 0.00 2735926.00 0.00 2735926.00 2735926.00 N 5.6 PN The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Redmile Biopharma Investments III, L.P. ("RBI III") is incorporated herein by reference. Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Form 20-F. AgomAb Therapeutics NV Posthoflei 1/6, 2600 Antwerpen, Belgium Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P. Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware Y There is no CUSIP number assigned to the Common Shares. CUSIP number 00860C102 has been assigned to the American Depositary Shares (ADSs) of the Issuer. Redmile Group, LLC - 2,735,926 (1) Jeremy C. Green - 2,735,926 (1) Redmile Biopharma Investments III, L.P. - 2,735,926 (1) Redmile Group, LLC - 5.6% (2) Jeremy C. Green - 5.6% (2) Redmile Biopharma Investments III, L.P. - 5.6% (2) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 2,735,926 (1) Jeremy C. Green - 2,735,926 (1) Redmile Biopharma Investments III, L.P. - 2,735,926 (1) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 2,735,926 (1) Jeremy C. Green - 2,735,926 (1) Redmile Biopharma Investments III, L.P. - 2,735,926 (1) (1) As of March 31, 2026, each of the reporting person's beneficial ownership of Common Shares is comprised of 2,579,676 Common Shares and 156,250 American Depositary Shares ("ADS"), each representing one Common Share. The Common Shares and ADS are directly held by RBI III, a private investment vehicle for which Redmile is the investment manager. Redmile may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all Common Shares held by RBI III. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) Percentage based on 49,247,975 Common Shares outstanding as of March 31, 2026, as reported by the Issuer in the Form 20-F. Y Y N See the response to Item 4. Y Y Y Redmile Group, LLC /s/ Jeremy C. Green 05/15/2026 Jeremy C. Green /s/ Jeremy C. Green 05/15/2026 Redmile Biopharma Investments III, L.P. /s/ Jeremy C. Green 05/15/2026